RCS - Creo Medical Group - MicroBlate™ Flex begins lung tumour clinical study

Creo MedicalAnnouncement

10/07/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250710:nRSJ4460Qa&default-theme=true

RNS Number : 4460Q  Creo Medical Group PLC  10 July 2025

Creo Medical Group plc

("Creo" or the "Company")

 

MicroBlate™ Flex begins landmark lung tumour post-market clinical study

 

Further step in the execution of Creo Medical's growth strategy

 

Creo Medical Group plc (AIM: CREO), the medical device company focused on the
emerging field of minimally invasive surgical endoscopy for pre-cancer and
cancer patients, announces the first patient treated in a new post-market
multi-centre "ablate and resect" clinical study (the "Study") evaluating the
safety and performance of its MicroBlate™ Flex for the treatment of lung
tumours.

 

In the Study, patients who are scheduled for lung tumour resection first
undergo ablation with Creo's MicroBlate™ Flex device.  Once surgically
removed, the tumour is analysed to assess device performance against the
patient's pre and post-procedural scans, a vital performance measure only
achievable from this study design. The Study is taking place at the Amsterdam
University Medical Centre in the Netherlands and at the Royal Brompton
Hospital in the UK.

 

Full details of the Study can be found here:
https://clinicaltrials.gov/study/NCT06689488
(https://clinicaltrials.gov/study/NCT06689488)

 

The Study complements Creo's previously announced post-market study designed
to gather immediate safety and longer-term follow-up clinical data. These
studies, in conjunction with the post-market programme underway with Intuitive
which delivers robotically-guided lung tumour ablation using Creo's
MicroBlate™ Flex alongside Intuitive's Ion endoluminal system, will provide
a substantial and robust clinical dataset ahead of commercialisation.

 

About MicroBlate™ Flex

MicroBlate™ Flex is a soft tissue ablation device, designed to ablate
nodules and tumours in several tissue types. Lung tumour ablation is a
potential critical application for MicroBlate™ Flex. Lung cancer is the
most common cancer in men and the second most common cancer in women.
Treatment options are currently sub optimal and typically involve
chemotherapy, radiation therapy, surgery or a combination thereof. The unique
design of MicroBlate™ Flex offers patients the prospect of a significantly
less invasive outcome when treating lung tumours.

 

Commenting, Craig Gulliford, Chief Executive Officer, said:

"We're delighted to see the start of an additional clinical study to generate
data on MicroBlate™ Flex, which we believe has the potential to become an
invaluable tool for treating early lung cancers or metastatic tumours in the
lung, whilst minimising damage to health parts of the lung. Our collaboration
with Intuitive further strengthens our emerging position at the forefront of
minimally invasive lung cancer treatment and highlights the broad potential of
MicroBlate™ Flex as we move toward commercialisation."

 

For further information please contact:

 

 Creo Medical Group plc                                                        www.creomedical.com
                                                                               (https://protect.checkpoint.com/v2/___http:/www.creomedical.com/___.YzJ1OmludHVpdGl2ZTpjOm86NWJlYzBmMzJjY2MyZTBiZWFkNmJkZmVmNzdhM2MwMTI6NjoyYWU4OjczNzQyNWUwODBjYTEwNzAxYWMzNWEyZDQ3YzI1ZmEwYWMzYTc4M2Q2M2NjYzEyNTQwZWM3ODc4NTk3NTE4YTQ6cDpUOk4)
 Richard Craven, Company Secretary                                             Via Walbrook PR

 Deutsche Numis (Nominated Adviser, sole Broker and Financial Adviser)         +44 (0)20 7260 1000

 Freddie Barnfield / Duncan Monteith / Sher Shah

 Walbrook PR Ltd                      Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com (mailto:creo@walbrookpr.com)
 Paul McManus / Alice Woodings        Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654

 

About Creo Medical

Creo Medical is a medical device company focused on the development and
commercialisation of minimally invasive electrosurgical devices, bringing
advanced energy to endoscopy.

 

The Company's vision is to improve patient outcomes through the development
and commercialisation of a suite of electrosurgical medical devices, each
enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA
powered by Kamaptive full-spectrum adaptive technology to optimise surgical
capability and patient outcomes. Kamaptive is a seamless, intuitive
integration of multi-modal energy sources, optimised to dynamically adapt to
patient tissue during procedures such as resection, dissection, coagulation
and ablation of tissue. Kamaptive technology provides clinicians with
increased flexibility, precision and controlled surgical solutions. CROMA
currently delivers bipolar radiofrequency ("RF") energy for precise localised
cutting and focused high frequency microwave ("MW") energy for controlled
coagulation and ablation via a single accessory port. This technology,
combined with the Group's range of patented electrosurgical devices, is
designed to provide clinicians with flexible, accurate and controlled clinical
solutions. The Directors believe the Company's technology can impact the
landscape of surgery and endoscopy by providing a safer, less-invasive and
more cost-efficient option for procedures.

 

For more information, please refer to the website www.creomedical.com
(http://www.creomedical.com)

 

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAUPUUPMUPAGRB